Co-Diagnostics (NASDAQ:CODX) is a molecular diagnostics company specializing in the development, manufacture and sale of diagnostic tests for the detection of human disease. Founded in 2013 and headquartered in Salt Lake City, Utah, the company leverages its proprietary CoPrimer® technology to design highly specific and sensitive real-time polymerase chain reaction (qPCR) assays. By focusing on the core principles of accuracy, affordability and ease of use, Co-Diagnostics has positioned itself as a key innovator in the PCR-based testing market.
The company’s primary product offerings include CoPrimer-based assay kits and related reagents for a variety of infectious diseases, with an initial emphasis on respiratory pathogens. Co-Diagnostics gained significant attention during the COVID-19 pandemic for its rapid development and commercialization of a PCR test kit that received Emergency Use Authorization from the U.S. Food and Drug Administration (FDA). Beyond COVID-19, the firm’s pipeline encompasses assays for influenza, tuberculosis, Zika virus, dengue fever and other emerging pathogens, enabling laboratories and healthcare providers worldwide to conduct reliable molecular testing.
Co-Diagnostics operates through direct sales and a network of global distributors, serving customers in North America, Europe, Latin America, the Middle East and parts of Asia. Its tests are compatible with most standard real-time PCR instruments, allowing clinical laboratories and public health agencies to integrate Co-Diagnostics assays into existing workflows without the need for proprietary hardware. The company also collaborates with manufacturing partners to scale production of assay components and offers technical support and validation services to ensure seamless implementation.
Under the leadership of Chief Executive Officer Dwight Egan, Co-Diagnostics continues to invest in research and development to expand its product portfolio and respond to evolving public health needs. The management team includes seasoned professionals in molecular biology, regulatory affairs and commercial operations, all dedicated to advancing accessible diagnostics. Looking ahead, Co-Diagnostics aims to enhance its automation capabilities, pursue additional regulatory clearances and strengthen its global footprint in the fast-growing molecular diagnostics sector.
